Drug Profile
Research programme: cancer therapeutics - Affibody/Nuclisome
Latest Information Update: 02 Nov 2016
Price :
$50
*
At a glance
- Originator Affibody; Nuclisome AB
- Class Antineoplastics; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer